🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

AirSculpt Technologies, Inc. AIRS R2KPHARMA

Healthcare · Medical Care Facilities · United States
https://www.airsculpt.com
Company Profile ↓
$2.80
-61.71% 1Y
Mkt Cap$197.53M
P/E-16.47
P/B3.53
52W High$11.65
52W Low$1.58
Book Value$1.42
EPS (TTM)$-0.17

Company Overview

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States and Canada. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that transfers the patient's own fat cells to enhance the buttocks, breasts, hips, aging hands, or other areas. Further, the company's body contouring procedures include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. Additionally, it operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 29.8% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $151.82M (-15.8% YoY); net profit $-11.67M.
  • Trailing 12 Months Year-on-year growth — revenue +0.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 29.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:29.78%
1 Year:0.00%

Stock Price Performance

1 Year:-61.71%
6 Months:+33.73%
3 Months:-45.30%
1 Month:-41.40%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 12% of range
$1.58 $11.65
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)41.23 · Neutral
Price Performance
1M-41.40%
3M-45.30%
6M+33.73%
1Y-61.71%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 29.8% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 76.0% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-16.47
Industry PE
25.17
Forward P/E
280.00
PEG Ratio
-
Book Value
$1.42
Price to Book
3.53
P/S
2.33
EV/EBITDA
54.27
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
29.78%
Profit 5Y
-
Revenue (YoY)
0.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-3.03%
ROE
-12.63%
ROA
-1.60%
Profit Margin
-7.39%
Op Margin
-4.58%
Gross Margin
66.06%
EPS (Latest Qtr)
$-0.02
EPS (TTM)
$-0.17

Balance Sheet & Liquidity

Debt/Equity
0.71
Quick Ratio
0.57
Current Ratio
0.75
Debt
$71.02M
Total Assets
$193.28M
Current Assets
$24.33M
Working Capital
$-12.45M

Ownership

Promoter Holding
42.14%
Chg in Prom Hold
-0.93%
FII / Inst Holding
63.36%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$197.53M
Total Revenue (TTM)
$151.84M
EBITDA
$7.51M
Free Cash Flow
$13.02M
Operating Cash Flow
$7.50M
Shares Outstanding
70.55M
Gross Margin
66.06%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AIRS AirSculpt Technologies, Inc. R2KPHARMA 2.80 -16.47 $197.53M 0.00% -3.03% -12.63% 29.78% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 26.14M34.97M34.65M-39.54M49.65M38.89M45.81M55.70M46.79M47.62M51.00M--39.37M44.01M34.99M33.44M39.39M42.90M
Cost of Revenue --------------15.95M17.20M14.86M13.68M15.59M-
Gross Profit --------------23.42M26.81M20.13M19.77M23.80M-
Operating Expenses --------------25.01M25.92M22.74M21.29M25.60M-
Operating Income 7.21M11.20M9.62M--1.17M3.96M-1.38M1.76M5.36M955.00K11.01M-4.98M---1.59M894.00K-2.61M-1.52M-1.80M-29.00K
EBITDA --------------1.65M4.03M-6.53M2.07M1.36M-
Interest Expense --------------1.62M1.56M1.41M1.48M1.20M-
Pretax Income ---------------3.21M-776.00K-11.16M-2.49M-2.86M-
Tax Provision ---------------367.00K-185.00K-1.65M-3.77M-465.00K-
Net Income 6.62M10.03M8.05M-393.00K-693.00K583.00K-7.38M-14.00K1.78M-1.67M6.03M-3.21M---2.85M-591.00K-9.51M1.28M-2.40M-1.11M
Diluted EPS -----0.010.01-0.130.000.03-0.030.10-0.06---0.05-0.01-0.150.02-0.03-0.02

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 41.24M62.77M-168.79M195.92M180.35M151.82M
Cost of Revenue ---62.78M73.77M71.15M61.69M
Gross Profit ---106.01M122.14M109.20M90.13M
Operating Expenses ---109.48M112.63M110.77M94.96M
Operating Income 663.00K10.03M--3.47M9.51M-1.57M-4.83M
EBITDA ---3.52M19.98M10.30M1.22M
Interest Expense ---6.75M6.49M6.25M6.08M
Pretax Income ----11.30M3.24M-7.83M-17.64M
Tax Provision ---3.38M7.48M188.00K-5.97M
Net Income -2.21M7.58M--14.68M-4.24M-8.02M-11.67M
Diluted EPS ----0.26-0.08-0.14-0.19

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets 179.61M-200.76M204.02M212.78M187.30M
Current Assets --16.68M15.96M17.12M15.46M
Cash & Equivalents 10.38M-9.62M10.26M8.23M8.45M
Inventory ------
Receivables --2.83M1.94M3.06M1.50M
Total Liabilities 55.93M-129.99M120.03M134.59M99.59M
Current Liabilities 9.46M-22.32M20.32M28.95M27.90M
Long Term Debt 32.12M-81.42M69.50M70.46M50.59M
Total Debt --107.65M99.67M108.94M83.57M
Total Equity --70.77M83.99M78.19M87.71M
Shares Outstanding --56.18M57.36M58.37M64.54M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 4.94M13.96M-24.45M23.96M11.35M3.10M
Investing Cash Flow -4.44M-3.69M--12.92M-9.92M-14.01M-2.40M
Financing Cash Flow -783.00K-5.02M--27.26M-13.39M630.00K-478.00K
Capital Expenditure -4.44M-3.69M--12.92M-9.92M-14.01M-2.40M
Free Cash Flow 499.00K10.27M-11.53M14.04M-2.66M692.00K
Net Change in Cash ----15.73M646.00K-2.03M214.00K
Dividends Paid -0023.16M385.00K252.00K0

Ratios (Annual)

Figures in %.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---62.8%62.3%60.5%59.4%
Operating Margin % 1.6%16.0%--2.1%4.9%-0.9%-3.2%
Net Margin % -5.4%12.1%--8.7%-2.2%-4.4%-7.7%
ROE % ----20.7%-5.0%-10.3%-13.3%
ROCE % -5.9%--1.9%5.2%-0.9%-3.0%

Shareholding Pattern

Insiders
42.14%
Institutions
63.36%
Public Float
109.51%

Top Institutional Holders

#Holder% HeldSharesValue
1 Vesey Street Capital Partners, LLC 42.06% 30.32M $78.84M
2 Thrivent Financial For Lutherans 6.14% 4.42M $11.50M
3 Blackrock Inc. 1.77% 1.28M $3.33M
4 Wexford Capital LP 1.17% 841.73K $2.19M
5 UBS Group AG 1.10% 792.18K $2.06M
6 FourWorld Capital Management, LLC 1.04% 750.00K $1.95M
7 FLPutnam Investment Management Company 0.96% 691.99K $1.80M
8 AQR Capital Management, LLC 0.65% 470.72K $1.22M
9 Geode Capital Management, LLC 0.63% 451.22K $1.17M
10 GSA Capital Partners LLP 0.59% 425.19K $1.11M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AIRS

Yahoo Finance Mon, 17 Aug 2026

AirSculpt (AIRS) Q2 2026 Earnings Call Transcript

Same-center case growth turned positive for second consecutive quarter.

Yahoo Finance hu, 13 Aug 2026

AirSculpt Technologies (AIRS) After Q2 Results Is The Valuation Gap Still Real

AirSculpt Technologies (AIRS) is back in focus after reporting Q2 2026 results that showed slightly lower sales and a wider net loss, while management reaffirmed full year revenue guidance at the lower end of its range. See our latest analy…

Yahoo Finance Wed, 12 Aug 2026

AirSculpt Technologies Inc (AIRS) (Q2 2026) Earnings Call Highlights: Strategic Investments ...

Despite a 2.5% revenue dip, the company posts its second consecutive quarter of case growth and expands its procedure portfolio to capture the GLP-1 market.

Yahoo Finance ue, 11 Aug 2026

AirSculpt Sees Core Stabilization, Targets $100M-Plus GLP-1 Opportunity

AirSculpt Technologies (NASDAQ:AIRS) is seeing stabilization in its core body-contouring business after several quarters of declines, while expanding services aimed at patients using GLP-1 weight-loss drugs, Chief Executive Officer Yogi Jas…

Yahoo Finance Mon, 10 Aug 2026

AirSculpt Technologies Q2 Earnings Call Highlights

AirSculpt Technologies (NASDAQ:AIRS) reported second-quarter revenue of $42.9 million, down 2.5% from the prior-year period, as the company cited stable revenue trends, positive same-center case growth and continued investment in marketing …

Yahoo Finance Mon, 10 Aug 2026

AirSculpt Technologies shares plunge 13% after revenue miss and weaker EBITDA outlook

AirSculpt Technologies, Inc. (NASDAQ:AIRS) shares tumbled 13.

AIRS — Frequently Asked Questions

What is the current share price of AirSculpt Technologies, Inc. (AIRS)?

As of 2026-09-07 16:24 PDT, AirSculpt Technologies, Inc. (AIRS) trades at $2.80 on NasdaqGM. Its 52-week range is $1.58 to $11.65.

What is the market capitalisation of AIRS?

AirSculpt Technologies, Inc. (AIRS) has a market capitalisation of $197.53M on NasdaqGM.

What is the P/E ratio of AIRS?

AIRS trades at a trailing price-to-earnings (P/E) ratio of -16.47. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.53.

What is the return on equity (ROE) of AIRS?

AIRS has a return on equity (ROE) of -12.63%. Its return on capital employed (ROCE) is -3.03%.

Is AIRS a good stock to buy?

This page provides a data-driven analysis of AirSculpt Technologies, Inc. (AIRS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space